Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Accured Expenses (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Change in Accured Expenses for 12 consecutive years, with -$850000.0 as the latest value for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 60.97% year-over-year to -$850000.0; the TTM value through Mar 2026 reached -$2.3 million, up 9.35%, while the annual FY2025 figure was -$3.6 million, 46.77% up from the prior year.
  • Change in Accured Expenses hit -$850000.0 in Q1 2026 for Cartesian Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.2 million in Q2 2022 and bottomed at -$6.4 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is -$689882.4, with a median of -$432000.0 recorded in 2025.
  • Year-over-year, Change in Accured Expenses skyrocketed 716.67% in 2023 and then plummeted 222.78% in 2024.
  • Cartesian Therapeutics' Change in Accured Expenses stood at $1.6 million in 2022, then tumbled by 171.21% to -$1.1 million in 2023, then surged by 203.56% to $1.2 million in 2024, then decreased by 8.94% to $1.1 million in 2025, then plummeted by 180.26% to -$850000.0 in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$850000.0, $1.1 million, and -$432000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.